Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.

There are few data about the long-term histological outcome of HIV-/HCV-coinfected patients after therapy with interferon and ribavirin. We performed an observational study of 216 patients who received therapy against HCV and who had at least three successive transient elastographies (TE) during the follow-up. The primary endpoint was confirmed fibrosis regression, defined as a reduction of at least 1 point in Metavir fibrosis score, confirmed and without worsening in successive TE. At baseline, 23% had fibrosis stage 4 or cirrhosis. Overall, 82 (38%) achieved sustained virological response (SVR), without differences in baseline fibrosis or time of follow-up. Confirmed fibrosis regression was observed in 55% of patients, higher for SVR (71% vs 44%; P < 0.01), and the likelihood of achieving fibrosis regression at 3, 5 and 7 years was 0.17, 0.51 and 0.67, respectively, for SVR patients, in comparison with 0.02, 0.23 and 0.41 for no SVR patients (P < 0.01, log-rank test at any time point). Progressive regression, defined as continuous improvement in successive TE, was observed in 62% of patients with advanced liver fibrosis or cirrhosis who achieved SVR. In a Cox regression model, only SVR (HR, 4.01; 95% CI, 2.33-7.57; P < 0.01) and a younger age (HR, 1.14; 95% CI, 1.05-1.25; P < 0.01; per year) were associated with fibrosis regression. This study confirms that the rate of liver fibrosis regression increases during the follow-up after SVR to interferon therapy in HIV-/HCV-coinfected patients.
AuthorsJ L Casado, C Quereda, A Moreno, M J Pérez-Elías, P Martí-Belda, S Moreno
JournalJournal of viral hepatitis (J Viral Hepat) Vol. 20 Issue 12 Pg. 829-37 (Dec 2013) ISSN: 1365-2893 [Electronic] England
PMID24304452 (Publication Type: Journal Article, Observational Study)
Copyright© 2013 John Wiley & Sons Ltd.
Chemical References
  • Antiviral Agents
  • Ribavirin
  • Interferons
  • Adult
  • Antiviral Agents (therapeutic use)
  • Cohort Studies
  • Coinfection (complications, drug therapy)
  • Elasticity Imaging Techniques
  • Female
  • HIV Infections (complications)
  • Hepacivirus (isolation & purification)
  • Hepatitis C, Chronic (complications, drug therapy)
  • Humans
  • Interferons (therapeutic use)
  • Liver (pathology)
  • Liver Cirrhosis (pathology)
  • Male
  • Middle Aged
  • Ribavirin (therapeutic use)
  • Treatment Outcome
  • Viral Load

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: